CY1107987T1 - In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp) - Google Patents

In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp)

Info

Publication number
CY1107987T1
CY1107987T1 CY20061101462T CY061101462T CY1107987T1 CY 1107987 T1 CY1107987 T1 CY 1107987T1 CY 20061101462 T CY20061101462 T CY 20061101462T CY 061101462 T CY061101462 T CY 061101462T CY 1107987 T1 CY1107987 T1 CY 1107987T1
Authority
CY
Cyprus
Prior art keywords
vlps
reassegration
vlp
disassembly
particle
Prior art date
Application number
CY20061101462T
Other languages
English (en)
Inventor
Michael P. Mccarthy
Joann Suzich
Original Assignee
Medimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Inc. filed Critical Medimmune, Inc.
Publication of CY1107987T1 publication Critical patent/CY1107987T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Μια μέθοδος αποσυγκρότησης/επανασυγκρότησης VLP ιού θηλώματος παρέχεται. Τα προκύπτοντα VLP έχουν αυξημένη ομοιογένεια, εμφανίζουν εξουδετερωτικούς επιτόπους διαμόρφωσης PV, και είναι συνεπώς χρήσιμα μέσα πρόληψης και διάγνωσης. Επιπλέον, αυτά τα VLP μπορούν να χρησιμοποιηθούν για την ενκαψουλίωση επιθυμητών οντοτήτων, π.χ. θεραπευτικών ή διαγνωστικών μέσων, ή DNA «δεικτών», και τα προκύπτοντα VLP χρησιμοποιούνται ως in vivo οχήματα μεταφοράς ή ως ψευδοϊοσωμάτια για την αξιολόγηση της αποτελεσματικότητας εμβολίων.
CY20061101462T 1997-09-05 2006-10-12 In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp) CY1107987T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
PCT/US1998/016464 WO1999013056A1 (en) 1997-09-05 1998-08-19 IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)

Publications (1)

Publication Number Publication Date
CY1107987T1 true CY1107987T1 (el) 2011-04-06

Family

ID=25449564

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101462T CY1107987T1 (el) 1997-09-05 2006-10-12 In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp)
CY2007007C CY2007007I2 (el) 1997-09-05 2016-06-13 In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2007007C CY2007007I2 (el) 1997-09-05 2016-06-13 In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp)

Country Status (16)

Country Link
US (2) US6416945B1 (el)
EP (2) EP1015561B1 (el)
JP (2) JP4199416B2 (el)
AT (1) ATE333501T1 (el)
AU (1) AU742409B2 (el)
CA (1) CA2302545C (el)
CY (2) CY1107987T1 (el)
DE (3) DE69835294T2 (el)
DK (1) DK1015561T3 (el)
ES (2) ES2268787T3 (el)
FR (1) FR07C0012I2 (el)
HK (1) HK1030797A1 (el)
LU (1) LU91314I2 (el)
NL (1) NL300264I2 (el)
PT (1) PT1015561E (el)
WO (1) WO1999013056A1 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
WO1998002548A2 (en) * 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Infectious papillomavirus pseudoviral particles
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
CA2875298A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
JP4746819B2 (ja) * 2000-09-18 2011-08-10 メディミューン，エルエルシー ワクチンの免疫原性を測定する試験管内検定
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 ***瘤假病毒及其制备方法
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
AU2003237528A1 (en) 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRUS PARTICULAR CONSTRUCT AND METHOD FOR THEIR EDUCATION UNDER PHYSIOLOGICAL CONDITIONS
EP1885394A4 (en) * 2005-06-01 2009-10-21 Dow Global Technologies Inc PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8481693B2 (en) * 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
AU2008251615B2 (en) 2007-05-08 2014-09-18 The United States of America, as represented by The Secretary, Department of Health and Human Services Office of Technology Transfer National Institute of Health Papillomavirus pseudoviruses for detection and therapy of tumors
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
JP2012530505A (ja) 2009-06-25 2012-12-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規ヒトパピローマウイルス（ｈｐｖ）タンパク質構築物及びｈｐｖ疾患の予防におけるそれらの使用
US20120164710A1 (en) * 2009-07-03 2012-06-28 Yuan Yuan Fan Method of preparation of a biological particulate structure
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
ES2729841T3 (es) 2013-09-18 2019-11-06 Aura Biosciences Inc Conjugados de partículas similares a virus para tratar tumores
CA2958222A1 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
EA201790944A1 (ru) * 2014-12-26 2017-11-30 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
KR20180083868A (ko) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
MX2018005468A (es) 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Terapia dirigida contra el cáncer.
EP3368559A4 (en) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
CA3081757A1 (en) 2017-11-06 2019-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer treatment utilizing pre-existing microbial immunity
US11946048B2 (en) 2017-11-14 2024-04-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Non-human papillomaviruses for gene delivery in vitro and in vivo
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
EP1015561A1 (en) 2000-07-05
NL300264I1 (nl) 2007-05-01
CA2302545A1 (en) 1999-03-18
JP2009057377A (ja) 2009-03-19
ES2268787T3 (es) 2007-03-16
FR07C0012I1 (el) 2007-03-30
ATE333501T1 (de) 2006-08-15
NL300264I2 (nl) 2008-06-02
JP2001515922A (ja) 2001-09-25
US6416945B1 (en) 2002-07-09
AU742409B2 (en) 2002-01-03
DE122007000015I2 (de) 2008-01-24
CA2302545C (en) 2012-04-03
DE69835294D1 (de) 2006-08-31
JP4486142B2 (ja) 2010-06-23
EP1700911A1 (en) 2006-09-13
CY2007007I2 (el) 2016-10-05
US6261765B1 (en) 2001-07-17
AU9015498A (en) 1999-03-29
DE122007000015I1 (de) 2007-05-24
FR07C0012I2 (fr) 2007-10-26
LU91314I9 (el) 2019-01-30
HK1030797A1 (en) 2001-05-18
LU91314I2 (fr) 2007-04-23
DK1015561T3 (da) 2006-11-13
EP1700911B1 (en) 2016-04-06
PT1015561E (pt) 2006-11-30
JP4199416B2 (ja) 2008-12-17
DE69835294T2 (de) 2007-07-26
WO1999013056A1 (en) 1999-03-18
ES2572628T3 (es) 2016-06-01
CY2007007I1 (el) 2009-11-04
EP1015561B1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
CY1107987T1 (el) In vitro μεθοδος αποσυγκροτησης/επανασυγκροτησης σωματιδιων που μοιαζουν με ιο θηλωματος (vlp)
DE69836753D1 (de) Papilloma virus capsomere impfstoff-formulierungen und deren verwendungen
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DK0742834T4 (da) Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle
CY1109967T1 (el) Μικροσωματιδια αποτελουμενα απο οιστραδιολη και χοληστερολη
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
CY1112140T1 (el) Ανασυνδυασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
AU2002305099A1 (en) Fatty alcohol drug conjugates
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
MXPA05002814A (es) Formulacion para agentes lipofilicos.
EP1778351A4 (en) VERIFICATION OF LESIONAL FEATURES WITH BEAM SHAPES
MXPA06010592A (es) Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
PT861084E (pt) Processo e composicao melhorados para cisplatina (cddp) terapeutica
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
BR0012735A (pt) Preparação solida, e, processo para produzir preparações
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
ES2148572T3 (es) Derivados hidrosolubles de epipodofilotoxina, su procedimiento de preparacion, su utilizacion a titulo de medicamento, y su utilizacion destinada a los tratamientos anticancerosos.
AU1955001A (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)